Literature DB >> 22471098

Diabetic nephropathy and multiorgan protection. Part I.

G H Gluhovschi1, Cristina Gluhovschi, A Vlad, R Timar, F Bob, Silvia Velciov, G H Bozdog, Ligia Petrica.   

Abstract

Diabetic nephropathy, one of the most important complications of diabetes mellitus, requires during its evolution protective measures defined as renoprotective. Since the complications of diabetes mellitus are not limited to diabetic nephropathy and as this is frequently associated with heart complications that require protective measures defined as cardioprotective, neurologic measures that require neuroprotection of the retina, of the large vessels etc., much more complex protective measures are necessary. The metabolic complications that are usually at the basis of the other complications at the level of the cell also impose measures of protection. Such an approach can have important practical consequences. It is a well-known fact that most patients with chronic kidney disease--CKD--do not reach final stages as in the meantime they decease because of cardiovascular diseases. Consequently, cardioprotective measures have to be associated with renoprotective ones, as well as protective measures that address other organs, in close connection with protective measures at metabolic level. The protective measures must also address to microcirculation, diabetic nephropathy being a disease that primarily affects microcirculation. Diabetes mellitus also frequently affects the large vessels, the circulatory system being usually affected in its complexity. The paper represents a synthesis of multiorganprotective measures in diabetic nephropathy, in diabetes mellitus, respectively, the concept of multiorgan protection finding in this disease an ideal domain of expression. The first part gives the main multiorgan measures: monitoring of blood pressure and, mainly, protection by means of the renine aldosterone (RAAS) system, multiorgan by intensive monitoring of glycaemia and by treatment of proteinuria. The second part presents the other protective measures used in diabetic nephropathy.

Entities:  

Mesh:

Year:  2011        PMID: 22471098

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  3 in total

Review 1.  Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.

Authors:  Robert C Stanton
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

2.  Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.

Authors:  Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

3.  Effects of a GSK-3β inhibitor on the renal expression levels of RANK, RANKL and NF-κB in a rat model of diabetic nephropathy.

Authors:  Yi-Xia Zhou; Li-Xin Shi; Hua Yang; Yi-Guo Long; L U Meng; Li-Sa Lv; Yang Zhang; Huan Yao; Long Li; Yan-Ni Yu
Journal:  Exp Ther Med       Date:  2016-03-24       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.